CSL enters U.S. agreements on pricing and expansion
- CSL signed agreements with the U.S. government to lower medicine costs and expand U.S. manufacturing.
- The agreements provide regulatory certainty regarding Section 232 tariffs without any material financial impact expected in FY27.
- The company aims to align Medicaid medicine prices with developed nations and expand its US$1.5 billion Illinois plasma facility.
CSL (ASX:CSL) has entered into agreements with the U.S. Department of Health and Human Services and the U.S. Department of Commerce to lower domestic drug prices and expand its local manufacturing footprint.
The agreement follows the company's March announcement to expand its plasma production capacity.
Under the terms of the deals, CSL will offer Medicaid access to its medicines at prices comparable to other developed nations and expand its Kankakee, Illinois, site as part of a US$1.5 billion investment.
CSL stated that the agreements provide greater certainty around U.S. drug pricing and Section 232 tariffs while expecting no material financial impact in FY27.
Following the announcement, the CSL share price was unchanged at $171.57.
The biotechnology firm specialises in developing plasma-derived therapies, influenza vaccines, and treatments for iron deficiency.
In August 2026, CSL reported FY26 revenue of US$15.8 billion alongside an ongoing cost reduction programme targeting US$550 million in annual savings by FY28.
